Terry A Jacobson

List of Publications by Year
in descending order

Version: 2024-02-01

181 papers	19,638 citations	11608 70 h-index	11288 136 g-index
185 all docs	185 docs citations	185 times ranked	17777 citing authors

#	Article	IF	Citations
1	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 2019, 380, 11-22.	13.9	2,153
2	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
3	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€"Full Report. Journal of Clinical Lipidology, 2015, 9, 129-169.	0.6	632
4	Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease. Circulation, 2017, 135, e867-e884.	1.6	484
5	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, e38-e81.	1.1	431
6	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology, 2015, 9, S1-S122.e1.	0.6	430
7	Risk for Myopathy With Statin Therapy in High-Risk Patients. Archives of Internal Medicine, 2003, 163, 553.	4.3	404
8	National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 â€" executive summary. Journal of Clinical Lipidology, 2014, 8, 473-488.	0.6	396
9	Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. Journal of Clinical Lipidology, 2012, 6, 208-215.	0.6	395
10	An assessment by the Statin Muscle Safety Task Force: 2014 update. Journal of Clinical Lipidology, 2014, 8, S58-S71.	0.6	391
11	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. Journal of Clinical Lipidology, 2015, 9, 758-769.	0.6	390
12	Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. American Journal of Cardiology, 2006, 97, S89-S94.	0.7	370
13	Safety Considerations with Fibrate Therapy. American Journal of Cardiology, 2007, 99, S3-S18.	0.7	332
14	Meta-Analysis of the Relationship Between Nonâ€"High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology, 2009, 53, 316-322.	1.2	327
15	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2019, 13, 374-392.	0.6	315
16	Development and Evaluation of the Adherence to Refills and Medications Scale (ARMS) among Low-Literacy Patients with Chronic Disease. Value in Health, 2009, 12, 118-123.	0.1	286
17	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation, 2019, 140, e673-e691.	1.6	282
18	Effect of a Pharmacist Intervention on Clinically Important Medication Errors After Hospital Discharge. Annals of Internal Medicine, 2012, 157, 1.	2.0	271

#	Article	IF	Citations
19	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
20	Statin-induced myopathy: a review and update. Expert Opinion on Drug Safety, 2011, 10, 373-387.	1.0	248
21	Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Current Atherosclerosis Reports, 2011, 13, 474-483.	2.0	246
22	Patient Literacy and Question-asking Behavior During the Medical Encounter: A Mixed-methods Analysis. Journal of General Internal Medicine, 2007, 22, 782-786.	1.3	242
23	Safety and efficacy of statin therapy. Nature Reviews Cardiology, 2018, 15, 757-769.	6.1	239
24	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
25	Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. Journal of Clinical Lipidology, 2012, 6, 5-18.	0.6	229
26	Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. American Journal of Cardiology, 2004, 94, 1140-1146.	0.7	221
27	The CardioMetabolic Health Alliance. Journal of the American College of Cardiology, 2015, 66, 1050-1067.	1.2	211
28	Development and Psychometric Evaluation of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) in Low-Literacy Patients With Chronic Disease. Journal of Nursing Measurement, 2007, 15, 203-219.	0.2	210
29	Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education. Journal of Clinical Lipidology, 2013, 7, 472-483.	0.6	210
30	Effects of Icosapent Ethyl on TotalÂIschemic Events. Journal of the American College of Cardiology, 2019, 73, 2791-2802.	1.2	208
31	The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Current Opinion in Lipidology, 2007, 18, 401-408.	1.2	203
32	Predictors of medication self-management skill in a low-literacy population. Journal of General Internal Medicine, 2006, 21, 852-856.	1.3	191
33	Development of an illustrated medication schedule as a low-literacy patient education tool. Patient Education and Counseling, 2007, 66, 368-377.	1.0	174
34	The Fats of Life. Archives of Internal Medicine, 2001, 161, 2185.	4.3	171
35	Flaxseed Oil Increases the Plasma Concentrations of Cardioprotective (n-3) Fatty Acids in Humans. Journal of Nutrition, 2006, 136, 83-87.	1.3	164
36	Managing Dyslipidemia in Chronic Kidney Disease. Journal of the American College of Cardiology, 2008, 51, 2375-2384.	1.2	164

#	Article	IF	Citations
37	Rationale and design of <scp>REDUCEâ€IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€"Intervention Trial. Clinical Cardiology, 2017, 40, 138-148.	0.7	154
38	The importance of nonâ€"HDL cholesterol reporting in lipid management. Journal of Clinical Lipidology, 2008, 2, 267-273.	0.6	145
39	Usefulness of Omega-3 Fatty Acids and the Prevention of Coronary Heart Disease. American Journal of Cardiology, 2005, 96, 1521-1529.	0.7	139
40	Toward â€œPain-Freeâ€•Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings, 2008, 83, 687-700.	1.4	136
41	An assessment by the Statin Intolerance Panel: 2014 update. Journal of Clinical Lipidology, 2014, 8, S72-S81.	0.6	135
42	30-Year Trends in Serum Lipids Among United States Adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999â€"2006. American Journal of Cardiology, 2010, 106, 969-975.	0.7	133
43	Nonâ€"High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification. Journal of the American College of Cardiology, 2011, 58, 457-463.	1.2	132
44	Use of a Low-Literacy Patient Education Tool to Enhance Pneumococcal Vaccination Rates. JAMA - Journal of the American Medical Association, 1999, 282, 646.	3.8	130
45	Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. Journal of Clinical Lipidology, 2014, 8, 554-561.	0.6	128
46	Role of nâ^'3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. American Journal of Clinical Nutrition, 2008, 87, 1981S-1990S.	2.2	125
47	Statin Safety: Lessons from New Drug Applications for Marketed Statins. American Journal of Cardiology, 2006, 97, S44-S51.	0.7	122
48	Medication Use Among Inner-City Patients After Hospital Discharge: Patient-Reported Barriers and Solutions. Mayo Clinic Proceedings, 2008, 83, 529-535.	1.4	121
49	NLA Task Force on Statin Safety - 2014 update. Journal of Clinical Lipidology, 2014, 8, S1-S4.	0.6	114
50	Hypertriglyceridemia and cardiovascular risk reduction. Clinical Therapeutics, 2007, 29, 763-777.	1.1	113
51	Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Education and Counseling, 2010, 81, 177-181.	1.0	113
52	Statin Safety: An Assessment Using an Administrative Claims Database. American Journal of Cardiology, 2006, 97, S61-S68.	0.7	111
53	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. American Journal of Cardiology, 2012, 110, 1468-1476.	0.7	108
54	The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. Journal of Clinical Lipidology, 2021, 15, 33-60.	0.6	105

#	Article	IF	Citations
55	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
56	Effects of Niacin on Glucose Control in Patients With Dyslipidemia. Mayo Clinic Proceedings, 2008, 83, 470-478.	1.4	101
57	Health literacy and the quality of physicianâ€patient communication during hospitalization. Journal of Hospital Medicine, 2010, 5, 269-275.	0.7	100
58	National Lipid Association Annual Summary of Clinical Lipidology 2016. Journal of Clinical Lipidology, 2016, 10, S1-S43.	0.6	99
59	Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. Journal of Clinical Lipidology, 2016, 10, 833-841.	0.6	92
60	Medication Use Among Inner-City Patients After Hospital Discharge: Patient-Reported Barriers and Solutions. Mayo Clinic Proceedings, 2008, 83, 529-535.	1.4	90
61	The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovascular Drugs and Therapy, 2017, 31, 179-186.	1.3	89
62	Fluvastatin with and without niacin for hypercholesterolemia. American Journal of Cardiology, 1994, 74, 149-154.	0.7	88
63	Lipoprotein(a), Cardiovascular Disease, and Contemporary Management. Mayo Clinic Proceedings, 2013, 88, 1294-1311.	1.4	87
64	Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. Journal of Clinical Lipidology, 2017, 11, 880-890.	0.6	85
65	Toward â€œPain-Freeâ€•Statin Prescribing: Clinical Algorithm for Diagnosis and Management of Myalgia. Mayo Clinic Proceedings, 2008, 83, 687-700.	1.4	83
66	Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs. American Journal of Cardiology, 2007, 99, S47-S55.	0.7	81
67	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Journal of the American College of Cardiology, 2019, 74, 1159-1161.	1.2	79
68	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of Clinical Lipidology, 2019, 13, 860-872.	0.6	79
69	Clinical research in low-literacy populations: using teach-back to assess comprehension of informed consent and privacy information. IRB: Ethics & Human Research, 2008, 30, 13-9.	0.8	79
70	Myopathy with statinâ€“fibrate combination therapy: clinical considerations. Nature Reviews Endocrinology, 2009, 5, 507-518.	4.3	72
71	Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data. Archives of Internal Medicine, 2000, 160, 1361.	4.3	70
72	Identifying and Assisting Low-Literacy Patients with Medication Use: A Survey of Community Pharmacies. Annals of Pharmacotherapy, 2005, 39, 1441-1445.	0.9	70

#	Article	IF	Citations
73	Evidence-Based Management of Statin Myopathy. Current Atherosclerosis Reports, 2010, 12, 322-330.	2.0	70
74	Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. Journal of Clinical Lipidology, 2020, 14, 398-413.	0.6	70
75	Maximizing the Cost-effectiveness of Lipid-Lowering Therapy. Archives of Internal Medicine, 1998, 158, 1977.	4.3	69
76	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of Clinical Lipidology, 2021, 15, 629-648.	0.6	69
77	National Lipid Association Annual Summary of Clinical Lipidology 2015. Journal of Clinical Lipidology, 2014, 8, S1-S36.	0.6	64
78	Improving Medication Adherence through Graphically Enhanced Interventions in Coronary Heart Disease (IMAGE-CHD): A Randomized Controlled Trial. Journal of General Internal Medicine, 2012, 27, 1609-1617.	1.3	63
79	Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia. American Journal of Medicine, 2014, 127, 36-44.e1.	0.6	62
80	Low literacy is associated with uncontrolled blood pressure in primary care patients with hypertension and heart disease. Patient Education and Counseling, 2014, 96, 165-170.	1.0	61
81	New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol. Archives of Internal Medicine, 1999, 159, 1049.	4.3	60
82	Rationale and Design of the Pharmacist Intervention for Low Literacy in Cardiovascular Disease (PILL-CVD) Study. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 212-219.	0.9	58
83	Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial. Journal of General Internal Medicine, 2016, 31, 470-477.	1.3	58
84	Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2012, 6, 450-461.	0.6	54
85	Secondary Prevention of Coronary Artery Disease with Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 61-70.	0.7	53
86	Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis, 2014, 235, 585-591.	0.4	53
87	Long-term treatment of hypercholesterolemia with dietary fiber. American Journal of Medicine, 1994, 97, 504-508.	0.6	52
88	Fibrates in Combination With Statins in the Management of Dyslipidemia. Journal of Clinical Hypertension, 2006, 8, 35-41.	1.0	52
89	Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?. Mayo Clinic Proceedings, 2010, 85, 440-445.	1.4	52
90	Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. Journal of Clinical Lipidology, 2017, 11, 891-900.	0.6	49

#	Article	IF	Citations
91	Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia. Drug Safety, 2006, 29, 421-448.	1.4	48
92	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
93	Clinical characterization and molecular mechanisms of statin myopathy. Expert Review of Cardiovascular Therapy, 2008, 6, 955-969.	0.6	45
94	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for Obesity and Related Diseases, 2016, 12, 468-495.	1.0	45
95	Omega-3 Fatty Acids for Cardiovascular Disease Prevention. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 365-380.	0.4	44
96	Development and Implementation of a Health Literacy Training Program for Medical Residents. Medical Education Online, 2006, 11, 4612.	1.1	41
97	Introduction. American Journal of Medicine, 2001, 110, 1-2.	0.6	40
98	Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study. Journal of Clinical Lipidology, 2014, 8, 69-76.	0.6	40
99	Low-Literacy Interventions to Promote Discussion of Prostate Cancer. American Journal of Preventive Medicine, 2007, 33, 83-90.	1.6	39
100	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. Journal of Clinical Lipidology, 2016, 10, 33-57.	0.6	39
101	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2021, 144, 1845-1855.	1.6	39
102	A â€œHotâ€•Topic in Dyslipidemia Managementâ€”â€œHow to Beat a Flushâ€• Optimizing Niacin Tolerability to Promote Long-term Treatment Adherence and Coronary Disease Prevention. Mayo Clinic Proceedings, 2010, 85, 365-379.	1.4	37
103	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation, 2021, 144, 1750-1759.	1.6	36
104	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With PriorÂMyocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	1.2	36
105	Clinical context: Current concepts of coronary heart disease management. American Journal of Medicine, 2001, 110, 3-11.	0.6	35
106	Effect of health information technology interventions on lipid management in clinical practice: A systematic review of randomized controlled trials. Journal of Clinical Lipidology, 2013, 7, 546-560.	0.6	34
107	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. Journal of Clinical Lipidology, 2013, 7, 102-108.	0.6	34
108	Beyond lipids: The role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. Current Atherosclerosis Reports, 2007, 9, 145-153.	2.0	33

#	Article	IF	Citations
109	The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. Journal of Clinical Lipidology, 2019, 13, 415-424.	0.6	33
110	Opening a New Lipid â€œApo-thecaryâ€: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings, 2011, 86, 762-780.	1.4	32
111	Changes in Plasma Cholesterol Levels after Hospitalization for Acute Coronary Events. Cardiology, 1996, 87, 194-199.	0.6	30
112	Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Cardiovascular Drugs and Therapy, 2016, 30, 305-313.	1.3	30
113	Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy. Journal of the American College of Cardiology, 2017, 70, 1680-1681.	1.2	27
114	Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety. American Journal of Cardiology, 1994, 73, D25-D29.	0.7	26
115	Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study. Current Medical Research and Opinion, 2006, 22, 1065-1073.	0.9	26
116	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€IT PCI. Journal of the American Heart Association, 2022, 11, e022937.	1.6	26
117	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	1.2	25
118	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Cardiology Clinics, 2015, 33, 181-196.	0.9	24
119	Combination lipid-altering therapy: An emerging treatment paradigm for the 21st century. Current Atherosclerosis Reports, 2001, 3, 373-382.	2.0	23
120	Fluvastatin. Drugs, 2004, 64, 1305-1323.	4.9	23
121	The Safety of Aggressive Statin Therapy: How Much Can Low-Density Lipoprotein Cholesterol Be Lowered?. Mayo Clinic Proceedings, 2006, 81, 1225-1231.	1.4	23
122	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e61-e63.	1.4	23
123	Efficacy and Safety of Pravastatin in African Americans With Primary Hypercholesterolemia. Archives of Internal Medicine, 1995, 155, 1900.	4.3	22
124	Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated. Mayo Clinic Proceedings, 2008, 83, 1316-1325.	1.4	22
125	Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings fromÂaÂworkshop. Journal of Clinical Lipidology, 2013, 7, 573-609.	0.6	22
126	Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. Journal of Clinical Lipidology, 2013, 7, 399-407.	0.6	22

#	Article	IF	Citations
127	New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Endocrinology and Metabolism Clinics of North America, 2016, 45, 17-37.	1.2	22
128	Provider recommendations for patient-reported muscle symptoms on statin therapy: Insights from the Understanding Statin Use in America and Gaps in Patient Education survey. Journal of Clinical Lipidology, 2018, 12, 78-88.	0.6	22
129	Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitor Therapy in the Managed Care Era. American Journal of Cardiology, 1996, 78, 32-41.	0.7	20
130	Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. Current Opinion in Lipidology, 1997, 8, 369-374.	1.2	19
131	Development and evaluation of a medication counseling workshop for physicians: can we improve on â€˜take two pills and call me in the morningâ€™?. Medical Education Online, 2011, 16, 7133.	1.1	17
132	Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY. Journal of Clinical Lipidology, 2016, 10, 15-32.	0.6	17
133	Fluvastatin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy. American Journal of Medicine, 1994, 96, S64-S68.	0.6	16
134	Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. Current Atherosclerosis Reports, 2010, 12, 34-42.	2.0	16
135	Metabolic syndrome is associated with muscle symptoms among statin users. Journal of Clinical Lipidology, 2016, 10, 1022-1029.	0.6	16
136	Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opinion on Drug Safety, 2003, 2, 269-286.	1.0	15
137	Quality of Care in African-American Patients Admitted for Congestive Heart Failure at a University Teaching Hospital. American Journal of Cardiology, 2006, 97, 690-693.	0.7	15
138	Avoiding statin myopathy: understanding key drug interactions. Clinical Lipidology, 2011, 6, 665-674.	0.4	15
139	Dyslipidemia in Patients with Kidney Disease. Cardiology Clinics, 2021, 39, 353-363.	0.9	14
140	Comparison of African-American Patients With Systolic Heart Failure Versus Preserved Ejection Fraction. American Journal of Cardiology, 2006, 98, 806-808.	0.7	13
141	Estimating Health and Economic Benefits from Using Prescription Omega-3 Fatty Acids in Patients With Severe Hypertriglyceridemia. American Journal of Cardiology, 2011, 108, 691-697.	0.7	13
142	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCEâ€IT. Journal of the American Heart Association, 2022, 11, e024999.	1.6	13
143	Efficacy and safety of alirocumab in statin-intolerant patients over 3Âyears: open-label treatment period of the ODYSSEY ALTERNATIVE trial. Journal of Clinical Lipidology, 2020, 14, 88-97.e2.	0.6	12
144	Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Current Atherosclerosis Reports, 2017, 19, 29.	2.0	11

#	Article	IF	Citations
145	Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3Âtrials. Journal of Clinical Lipidology, 2019, 13, 586-593.e5.	0.6	11
146	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 2022, 5, e2148172.	2.8	11
147	Initiating statins in the elderly: the evolving challenge. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 182-187.	1.2	9
148	Omega-3 Fatty Acids. , 2009, , 326-338.		9
149	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)Â©. Patient, 2017, 10, 321-334.	1.1	9
150	An assessment of obesity among African-American women in an inner city primary care clinic. Journal of the National Medical Association, 2002, 94, 1049-57.	0.6	9
151	Chronic kidney disease and statins: Improving cardiovascular outcomes. Current Atherosclerosis Reports, 2009, 11, 301-308.	2.0	8
152	A new pure Ï‰-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Review of Cardiovascular Therapy, 2012, 10, 687-695.	0.6	8
153	Hospital use and medical care costs up to 5 years after triglyceride lowering among patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2012, 6, 443-449.	0.6	8
154	Cost-Effectiveness of Fluvastatin following Successful First Percutaneous Coronary Intervention. Annals of Pharmacotherapy, 2005, 39, 610-616.	0.9	7
155	Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology, 2010, 33, 609-619.	0.7	7
156	Treating isolated low high-density lipoprotein cholesterol: prescient or premature?. American Journal of Cardiology, 2000, 85, 484-486.	0.7	6
157	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. American Journal of Cardiology, 2003, 91, 1134-1136.	0.7	6
158	Effects of race on Lipid-Lowering management in hospitalized patients with coronary heart disease. American Journal of Cardiology, 2004, 93, 1167-1170.	0.7	6
159	Achieving adherence to lipid-lowering regimens. Journal of Clinical Lipidology, 2013, 7, 4-13.	0.6	5
160	Fluvastatin, Rhabdomyolysis, and Myotoxicityâ€“Replyâ€“I. Mayo Clinic Proceedings, 2008, 83, 1297.	1.4	4
161	Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Low-Density Lipoprotein Cholesterol: A Critical Review. Journal of Clinical Lipidology, 2011, 5, 200-201.	0.6	4
162	Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology, 2011, 6, 131-136.	0.4	4

#	Article	IF	Citations
163	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clinical Lipidology, 2014, 9, 149-161.	0.4	4
164	Fluvastatin, Rhabdomyolysis, and Myotoxicity. Mayo Clinic Proceedings, 2008, 83, 1296-1297.	1.4	3
165	Unblinded ASCOT study results do not rule out that muscle symptoms are an adverse effect of statins. Evidence-Based Medicine, 2017, 22, 210-210.	0.6	3
166	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. Journal of Clinical Lipidology, 2020, 14, 4-15.	0.6	3
167	Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology, 2010, 5, 627-649.	0.4	2
168	Authors' reply to commentary entitled â€œEPA and DHA: Distinct yet essential n-3 fatty acidsâ€• Journal of Clinical Lipidology, 2012, 6, 477-479.	0.6	2
169	Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin. Current Medical Research and Opinion, 2013, 29, 773-781.	0.9	2
170	Beta-human Chorionic Gonadotropin-producing Renal Cell Carcinoma. American Journal of Medicine, 2016, 129, e29-e31.	0.6	2
171	Primary Prevention With Metoprolol in Patients With Hypertension. JAMA - Journal of the American Medical Association, 1988, 260, 1715.	3.8	1
172	Effect of baseline plasma fatty acids on eicosapentaenoic acid levels in individuals supplemented with Î±-linolenic acid. International Journal of Food Sciences and Nutrition, 2009, 60, 28-37.	1.3	1
173	Using Apolipoprotein B to Manage Dyslipidemiaâ€“Replyâ€“I. Mayo Clinic Proceedings, 2010, 85, 769-771.	1.4	1
174	Quitting Smoking: Nicotine vs Placebo Gum. JAMA - Journal of the American Medical Association, 1989, 262, 773.	3.8	0
175	Formulary policy for cholesterol reduction. Journal of General Internal Medicine, 1991, 6, 266-267.	1.3	0
176	Inhaled anticholinergics and the long-term treatment of chronic obstructive pulmonary disease: Weighing benefits and risks. Clinical Cornerstone, 2009, 9, 45-49.	1.0	0
177	Combination drug therapy for hyperlipidemia. Clinical Cardiology, 1994, 17, IV-28-IV-34.	0.7	0
178	Continuing Medical Education Program in the Journal of Hospital Medicine. Journal of Hospital Medicine, 2010, 5, 268-268.	0.7	0
179	Statins in patients with CKD prove beneficial in reducing cardiovascular events and mortality but show no benefit in patients on dialysis. Evidence-Based Medicine, 2013, 18, 175-176.	0.6	0
180	Authorsâ€™ response to letter by Anagnostis and Stevenson, â€œIs there aÂrole for menopausal hormone therapy in a woman with increased lipoprotein(a) concentrations?â€• Journal of Clinical Lipidology, 2020, 14, 156-157.	0.6	0

#	Article	IF	Citations
181	Improving the Cost Effectiveness of Lipid Lowering Therapy in Coronary Heart Disease Prevention. Medical Science Symposia Series, 1998, , 275-284.	0.0	0